12,111 Shares in Perrigo Company plc $PRGO Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new stake in shares of Perrigo Company plc (NYSE:PRGO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,111 shares of the company’s stock, valued at approximately $324,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. lifted its position in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares in the last quarter. Huntington National Bank increased its holdings in Perrigo by 237.8% in the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock worth $28,000 after acquiring an additional 742 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after acquiring an additional 424 shares during the period. Hantz Financial Services Inc. lifted its holdings in Perrigo by 101.0% during the second quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after purchasing an additional 620 shares in the last quarter. Finally, Picton Mahoney Asset Management bought a new position in shares of Perrigo in the first quarter worth approximately $42,000. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Trading Down 0.9%

Shares of PRGO stock opened at $14.17 on Thursday. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -24.42 and a beta of 0.42. Perrigo Company plc has a 12-month low of $14.12 and a 12-month high of $30.93. The stock’s 50-day moving average price is $20.78 and its 200-day moving average price is $24.19.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.05. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the business posted $0.81 EPS. The firm’s revenue for the quarter was down 4.1% compared to the same quarter last year. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Equities research analysts predict that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 16th. Investors of record on Friday, November 28th will be issued a $0.29 dividend. The ex-dividend date of this dividend is Friday, November 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.2%. Perrigo’s dividend payout ratio (DPR) is -305.26%.

Insider Buying and Selling at Perrigo

In other Perrigo news, EVP Robert Willis bought 1,488 shares of Perrigo stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $24.10 per share, for a total transaction of $35,860.80. Following the acquisition, the executive vice president directly owned 41,939 shares in the company, valued at approximately $1,010,729.90. This represents a 3.68% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Eduardo Guarita Bezerra bought 3,000 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were acquired at an average price of $22.74 per share, for a total transaction of $68,220.00. Following the completion of the transaction, the chief financial officer directly owned 48,949 shares in the company, valued at approximately $1,113,100.26. This represents a 6.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 10,118 shares of company stock worth $232,699 in the last ninety days. Company insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wall Street Zen cut shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Jefferies Financial Group cut their price target on Perrigo from $27.00 to $23.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Canaccord Genuity Group decreased their price target on Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Perrigo in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $20.00 target price (down previously from $32.00) on shares of Perrigo in a research report on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $22.50.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.